AMGEN and ALLERGAN plc. have submitted a Biologics License Application to FDA for ABP 215, a biosimilar candidate to Avastin (bevacizumab). ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on. The companies said they believe this submission is the first bevacizumab biosimilar application submitted to FDA.
Amgen, Allergan submit application for biosimilar bevacizumab
YOU MAY BE INTERESTED IN
The National Coalition for Cancer Survivorship has provided the Cancer History Project with a rich archive of its newsletters: the NCCS Networker, volumes 1-11.